NeoGenomics Inc (NEO)

Currency in USD
9.02
+0.41(+4.76%)
Closed·
9.10+0.08(+0.89%)
·
NEO is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
8.519.07
52 wk Range
4.7213.74
Key Statistics
Prev. Close
8.61
Open
8.67
Day's Range
8.51-9.07
52 wk Range
4.72-13.74
Volume
2.89M
Average Volume (3m)
1.92M
1-Year Change
37.0821%
Book Value / Share
6.47
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
NEO Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
14.19
Upside
+57.29%
Members' Sentiments
Bearish
Bullish
ProTips
Net income is expected to grow this year

NeoGenomics Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy

NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. In addition, the company offers molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients’ oncology programs covering discovery and commercialization. The company was founded in 2001 and is headquartered in Fort Myers, Florida.

NeoGenomics Inc SWOT Analysis


Strategic Crossroads
Neo Performance Materials faces pivotal decisions as it navigates market challenges and explores strategic alternatives, potentially reshaping its future in advanced materials
European Expansion
Delve into Neo's new agreement with a major European automotive supplier, signaling growth potential in the electric vehicle and green technology sectors
Market Dynamics
Explore the complexities of the rare earths market, including geopolitical factors, supply chain challenges, and Neo's positioning amidst industry volatility
Financial Outlook
Analysts project positive earnings for Neo, with Stifel setting a C$13.00 price target. The company's strategic review remains the primary value drive
Read full SWOT analysis

NeoGenomics Inc Earnings Call Summary for Q1/2026

  • Q1 2026 revenue reached $186.7M, beating forecast of $184.53M with 11% YoY growth; EPS matched expectations at $0.01
  • Clinical segment revenue surged 14% to $171.2M while non-clinical declined 15% to $15.5M due to pharma sector weakness
  • Adjusted EBITDA rose 27% YoY to $9M; company maintains strong cash position of $146M with current ratio of 4.26
  • Stock fell 3.14% to $8.34 in aftermarket trading despite revenue beat, with InvestingPro rating shares slightly overvalued
  • Management projects Q2 revenue of $196.41M and EPS of $0.03; targets free cash flow positive status this year
Last Updated: 2026/04/28, 23:48
Read Full Transcript

Compare NEO to Peers and Sector

Metrics to compare
NEO
Peers
Sector
Relationship
P/E Ratio
−10.9x−25.7x−0.5x
PEG Ratio
0.29−0.210.00
Price/Book
1.4x1.2x2.6x
Price / LTM Sales
1.6x3.7x3.2x
Upside (Analyst Target)
62.6%54.4%48.8%
Fair Value Upside
Unlock9.9%7.6%Unlock

Analyst Ratings

6 Buy
6 Hold
0 Sell
Ratings:
12 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 14.19
(+57.29% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
William Blair
Hold---MaintainMar 16, 2026
TD Cowen
Buy16.00+77.38%-MaintainMar 16, 2026
Leerink Partners
Hold14.00+55.21%-MaintainMar 16, 2026
Piper Sandler
Buy13.00+44.12%12.00MaintainFeb 24, 2026
Benchmark
Hold---MaintainFeb 18, 2026

Earnings

Latest Release
Apr 28, 2026
EPS / Forecast
0,01 / 0,01
Revenue / Forecast
187M / 184,53M
EPS Revisions
Last 90 days

NEO Income Statement

FAQ

What Is the NeoGenomics (NEO) Stock Price Today?

The NeoGenomics stock price today is 9,02 USD.

What Stock Exchange Does NeoGenomics Trade On?

NeoGenomics is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for NeoGenomics?

The stock symbol for NeoGenomics is "NEO."

What Is the NeoGenomics Market Cap?

As of today, NeoGenomics market cap is 1,17B USD.

What Is NeoGenomics's Earnings Per Share (TTM)?

The NeoGenomics EPS (TTM) is -0,84.

When Is the Next NeoGenomics Earnings Date?

NeoGenomics will release its next earnings report on Aug 05, 2026.

From a Technical Analysis Perspective, Is NEO a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Buy.

How Many Times Has NeoGenomics Stock Split?

NeoGenomics has split 2 times.

How Many Employees Does NeoGenomics Have?

NeoGenomics has 2500 employees.

What is the current trading status of NeoGenomics (NEO)?

As of Apr 29, 2026, NeoGenomics (NEO) is trading at a price of 9,02 USD, with a previous close of 8,61 USD. The stock has fluctuated within a day range of 8,51 USD to 9,07 USD, while its 52-week range spans from 4,72 USD to 13,74 USD.

What Is NeoGenomics (NEO) Price Target According to Analysts?

The average 12-month price target for NeoGenomics is 14,19 USD, with a high estimate of 17 USD and a low estimate of 12 USD. 6 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +57,29% Upside potential.

What Is the NEO Premarket Price?

NEO's last pre-market stock price is 8,34 USD. The pre-market share volume is 14 880,00, and the stock has decreased by -0,27, or -3,14%.

What Is the NEO After Hours Price?

NEO's last after hours stock price is 9,10 USD, the stock has decreased by 0,08, or 0,89%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.